Search

Your search keyword '"Scafuri, Luca"' showing total 48 results
Start Over Author "Scafuri, Luca"
48 results on '"Scafuri, Luca"'

2. Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy

Author

Scafuri, Luca, Buonerba, Carlo, Di Lauro, Vincenzo, Tortora, Vincenzo, Cascella, Marco, Liguori, Luigi, Sciarra, Antonella, Sabbatino, Francesco, Diana, Anna, Marra, Antonio, Tarantino, Paolo, Trapani, Dario, Giuliano, Mario, Arpino, Grazia, Curigliano, Giuseppe, and Di Lorenzo, Giuseppe

Published
2024
Full Text
View/download PDF

3. Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond

Author

Buonerba, Carlo, Ingenito, Concetta, Di Trolio, Rossella, Cappuccio, Francesca, Rubino, Roberta, Piscosquito, Arianna, Verde, Antonio, Costabile, Ferdinando, Iuliucci, Michela, Crocetto, Felice, Chiancone, Francesco, Nacchia, Antonio, Campitelli, Antonio, Scafuri, Luca, Sanseverino, Roberto, and Di Lorenzo, Giuseppe

Published
2024
Full Text
View/download PDF

5. A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario

Author

Di Lorenzo, Giuseppe, Michele, Aieta, Silvana, Leo, Bilancia, Domenico, Di Trolio, Rossella, Iuliucci, Michela Rosaria, Ingenito, Concetta, Rubino, Roberta, Piscosquito, Arianna, Caraglia, Michele, Donnarumma, Marianna, Costabile, Ferdinando, Conca, Raffaele, Pisino, Marco, Vaia, Angelo, Scafuri, Luca, Verde, Antonio, and Buonerba, Carlo

Published
2024
Full Text
View/download PDF

6. Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients

Author

Miglietta, Federica, Pontolillo, Letizia, De Angelis, Carmine, Caputo, Roberta, Marino, Monica, Bria, Emilio, Di Rienzo, Rossana, Verrazzo, Annarita, Buonerba, Carlo, Tortora, Giampaolo, Di Lorenzo, Giuseppe, Del Mastro, Lucia, Giuliano, Mario, Montemurro, Filippo, Puglisi, Fabio, Guarneri, Valentina, De Laurentiis, Michelino, Scafuri, Luca, and Arpino, Grazia

Published
2024
Full Text
View/download PDF

7. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis

Author

Ferro, Matteo, Crocetto, Felice, Tataru, Sabin, Barone, Biagio, Dolce, Pasquale, Lucarelli, Giuseppe, Sonpavde, Guru, Musi, Gennaro, Antonelli, Alessandro, Veccia, Alessandro, Terracciano, Daniela, Busetto, Gian Maria, Del Giudice, Francesco, Marchioni, Michele, Schips, Luigi, Porpiglia, Francesco, Fiori, Cristian, Carrieri, Giuseppe, Lasorsa, Francesco, Verde, Antonio, Scafuri, Luca, Buonerba, Carlo, and Di Lorenzo, Giuseppe

Published
2023
Full Text
View/download PDF

8. Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone

Author

Crocetto, Felice, Ferro, Matteo, Buonerba, Carlo, Bardi, Luca, Dolce, Pasquale, Scafuri, Luca, Mirto, Benito Fabio, Verde, Antonio, Sciarra, Antonella, Barone, Biagio, Calogero, Armando, Sagnelli, Caterina, Busetto, Gian Maria, Del Giudice, Francesco, Cilio, Simone, Sonpavde, Guru, Di Trolio, Rossella, Della Ratta, Giuseppe Luca, Barbato, Gabriele, and Di Lorenzo, Giuseppe

Published
2023
Full Text
View/download PDF

9. Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Author

Di Lorenzo, Giuseppe, Zappavigna, Silvia, Crocetto, Felice, Giuliano, Mario, Ribera, Dario, Morra, Rocco, Scafuri, Luca, Verde, Antonio, Bruzzese, Dario, Iaccarino, Simona, Costabile, Ferdinando, Onofrio, Livia, Viggiani, Martina, Palmieri, Alessandro, De Placido, Pietro, Marretta, Antonella Lucia, Pietroluongo, Erica, Luce, Amalia, Abate, Marianna, Navaeiseddighi, Zahrasadat, Caputo, Vincenzo Francesco, Celentano, Giuseppe, Longo, Nicola, Ferro, Matteo, Morelli, Franco, Facchini, Gaetano, Caraglia, Michele, De Placido, Sabino, and Buonerba, Carlo

Published
2021
Full Text
View/download PDF

10. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings

Author

Ferro, Matteo, Lucarelli, Giuseppe, Crocetto, Felice, Dolce, Pasquale, Verde, Antonio, La Civita, Evelina, Zappavigna, Silvia, de Cobelli, Ottavio, Di Lorenzo, Giuseppe, Facchini, Bianca Arianna, Scafuri, Luca, Onofrio, Livia, Porreca, Angelo, Busetto, Gian Maria, Sonpavde, Guru, Caraglia, Michele, Klain, Michele, Terracciano, Daniela, De Placido, Sabino, and Buonerba, Carlo

Published
2021
Full Text
View/download PDF

11. The Impact of Flavonoid Supplementation on Serum Oxidative Stress Levels Measured via D-ROMs Test in the General Population: The PREVES-FLAVON Retrospective Observational Study.

Author

Di Lorenzo, Giuseppe, Verde, Antonio, Scafuri, Luca, Costabile, Ferdinando, Caputo, Vincenza, Di Trolio, Rossella, Strianese, Oriana, Montanaro, Vittorino, Crocetto, Felice, Del Giudice, Francesco, Baio, Raffaele, Tufano, Antonio, Verze, Paolo, Calabrese, Alessia Nunzia, and Buonerba, Carlo

Abstract

Background: Oxidative stress has emerged as a key contributor to numerous NCDs (non-communicable diseases), including cardiovascular diseases, cancer, and diabetes. This study aims to explore the potential of targeted interventions to mitigate oxidative stress as part of a primary prevention strategy. Methods: The study included 32 healthy participants (11 men, 21 women) aged 45–65 who completed both the initial and follow-up assessments of the Healthy Days Initiative, a community-based wellness program organized by the non-profit Associazione O.R.A. ETS. Through blood analysis, vital sign assessment, lifestyle questionnaires, and individualized recommendations, participants received guidance on improving their health and reducing disease risk. The initiative also offered the opportunity for participants to consume a flavonoid supplement containing quercitrin, rutin, and hesperidin, with the goal of reducing oxidative stress. Participants who opted for supplementation were instructed to take 1–2 tablets daily for two weeks. Data collected included demographic information, anthropometric measurements, vital signs, dietary and lifestyle habits, medical history, WHO-5 Well-Being Index scores, and blood parameters. Results: Significant reductions were observed in glucose levels (from 82 to 74.5 mg/dL), reactive oxygen metabolites (d-ROMs) (from 394.5 to 365.5 U.CARR), and systolic blood pressure (from 133 to 122 mmHg) after the two-week flavonoid intervention. Most participants (26/31) reported no side effects, and the majority (30/31) expressed a willingness to continue using a product combination of quercitrin, rutin, and hesperidin or a similar product long-term. Conclusions: While limited in scope and duration, the PREVES-FLAVON study contributes valuable insights to the growing body of evidence suggesting that flavonoid supplementation may play a significant role in reducing risk factors associated with NCDs in primary prevention settings. By targeting novel risk factors such as oxidative stress, this intervention holds promise for mitigating the global burden of NCDs and promoting healthy aging. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Instant Messaging in Cancer Care.

Author

Buonerba, Carlo, Calabrese, Alessia Nunzia, Imperioso, Giuseppe, Piscosquito, Arianna, Verde, Antonio, Vaia, Angelo, Scafuri, Luca, Crocetto, Felice, Leopardo, Davide, Rocco, Bernardo, Del Giudice, Francesco, Tufano, Antonio, Casale, Beniamino, Cappuccio, Francesca, Chiancone, Francesco, Di Trolio, Rossella, and Di Lorenzo, Giuseppe

Subjects
TUMOR treatment, INSTANT messaging, MOBILE apps, CANCER patient medical care, PRIVACY, PATIENT care, COMMUNICATION, PHYSICIAN-patient relations, MEDICAL ethics
Abstract

The article focuses on the role of instant messaging in cancer care, particularly its potential to enhance doctor-patient communication. Topics discussed include the effectiveness of text messaging for preventive health behaviors, the impact of bidirectional communication on patient outcomes, and the challenges of continuous availability for healthcare professionals.

Published
2024
Full Text
View/download PDF

13. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis

Author

Buonerba, Carlo, Ferro, Matteo, Dolce, Pasquale, Crocetto, Felice, Verde, Antonio, Lucarelli, Giuseppe, Scafuri, Luca, Facchini, Sergio, Vaia, Angelo, Marinelli, Alfredo, Terracciano, Daniela, Montella, Liliana, Longo, Nicola, Imbimbo, Ciro, Mirone, Vincenzo, Di Lorenzo, Giuseppe, De Placido, Sabino, and Sonpavde, Guru

Published
2020
Full Text
View/download PDF

14. A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario

Author

Di Lorenzo, Giuseppe, primary, Michele, Aieta, additional, Silvana, Leo, additional, Bilancia, Domenico, additional, Di Trolio, Rossella, additional, Iuliucci, Michela Rosaria, additional, Ingenito, Concetta, additional, Rubino, Roberta, additional, Piscosquito, Arianna, additional, Caraglia, Michele, additional, Donnarumma, Marianna, additional, Costabile, Ferdinando, additional, Conca, Raffaele, additional, Pisino, Marco, additional, Vaia, Angelo, additional, Scafuri, Luca, additional, Verde, Antonio, additional, and Buonerba, Carlo, additional

Published
2023
Full Text
View/download PDF

16. PREVES: a population-based survey focused on cancer and nutrition

Author

Di Lorenzo, Giuseppe, primary, Ingenito, Concetta, additional, Iervolino, Mario, additional, Sosto, Gennaro, additional, Sergianni, Primo, additional, Primiano, Ferdinando, additional, Piscosquito, Arianna, additional, Iuliucci, Michela Rosaria, additional, Rubino, Roberta, additional, Gatani, Simona, additional, Ugliano, Francesco, additional, Scafuri, Luca, additional, Costabile, Ferdinando, additional, D'Ambrosio, Bruno, additional, D'Antonio, Alessandra, additional, Crescenzo, Antonio, additional, Cappuccio, Francesca, additional, and Buonerba, Carlo, additional

Published
2023
Full Text
View/download PDF

18. Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review

Author

Barone, Biagio, primary, Calogero, Armando, additional, Scafuri, Luca, additional, Ferro, Matteo, additional, Lucarelli, Giuseppe, additional, Di Zazzo, Erika, additional, Sicignano, Enrico, additional, Falcone, Alfonso, additional, Romano, Lorenzo, additional, De Luca, Luigi, additional, Oliva, Francesco, additional, Mirto, Benito Fabio, additional, Capone, Federico, additional, Imbimbo, Ciro, additional, and Crocetto, Felice, additional

Published
2022
Full Text
View/download PDF

21. The Effect of Vaccination against COVID-19 in Cancer Patients: Final Results of the COICA Trial

Author

Di Lorenzo, Giuseppe, primary, Ingenito, Concetta, additional, D’Ambrosio, Bruno, additional, Ranieri, Chiara, additional, Iuliucci, Michela Rosaria, additional, Iervolino, Mario, additional, Primiano, Ferdinando, additional, Buonerba, Luciana, additional, Busto, Giuseppina, additional, Ferrara, Claudia, additional, Libroia, Annamaria, additional, Ragone, Gianluca, additional, De Falco, Ferdinando, additional, Costabile, Ferdinando, additional, Fimiani, Pietro, additional, Ugliano, Francesco, additional, Leo, Emilio, additional, Roviello, Giandomenico, additional, Scafuri, Luca, additional, and Buonerba, Carlo, additional

Published
2022
Full Text
View/download PDF

22. The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study

Author

Di Lorenzo, Giuseppe, primary, Iervolino, Mario, additional, Primiano, Ferdinando, additional, D’Ambrosio, Maurizio, additional, Ingenito, Concetta, additional, Buonerba, Luciana, additional, Busto, Giuseppina, additional, Ferrara, Claudia, additional, Libroia, Annamaria, additional, Ragone, Gianluca, additional, De Falco, Ferdinando, additional, Costabile, Ferdinando, additional, Fimiani, Pietro, additional, Ugliano, Francesco, additional, Ranieri, Chiara, additional, Leo, Emilio, additional, Roviello, Giandomenico, additional, Scafuri, Luca, additional, Guerra, Germano, additional, and Buonerba, Carlo, additional

Published
2021
Full Text
View/download PDF

23. Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature

Author

Crocetto, Felice, primary, di Zazzo, Erika, additional, Buonerba, Carlo, additional, Aveta, Achille, additional, Pandolfo, Savio Domenico, additional, Barone, Biagio, additional, Trama, Francesco, additional, Caputo, Vincenzo Francesco, additional, Scafuri, Luca, additional, Ferro, Matteo, additional, Cosimato, Vincenzo, additional, Fusco, Ferdinando, additional, Imbimbo, Ciro, additional, and Di Lorenzo, Giuseppe, additional

Published
2021
Full Text
View/download PDF

26. Immune checkpoint inhibitors in penile cancer

Author

Buonerba, Carlo, primary, Scafuri, Luca, additional, Costabile, Ferdinando, additional, D’Ambrosio, Bruno, additional, Gatani, Simona, additional, Verolino, Pasquale, additional, Trolio, Rossella Di, additional, Cosimato, Vincenzo, additional, Verde, Antonio, additional, and Lorenzo, Giuseppe Di, additional

Published
2021
Full Text
View/download PDF

27. A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy

Author

Ferro, Matteo, primary, Lucarelli, Giuseppe, additional, de Cobelli, Ottavio, additional, Dolce, Pasquale, additional, Terracciano, Daniela, additional, Musi, Gennaro, additional, Porreca, Angelo, additional, Busetto, Gian Maria, additional, Del Giudice, Francesco, additional, Soria, Francesco, additional, Gontero, Paolo, additional, Cantiello, Francesco, additional, Damiano, Rocco, additional, Crocerossa, Fabio, additional, Abu Farhan, Abdal Rahman, additional, Autorino, Riccardo, additional, Vartolomei, Mihai Dorin, additional, Marchioni, Michele, additional, Mari, Andrea, additional, Minervini, Andrea, additional, Longo, Nicola, additional, Celentano, Giuseppe, additional, Chiancone, Francesco, additional, Perdonà, Sisto, additional, Del Prete, Paola, additional, Ditonno, Pasquale, additional, Battaglia, Michele, additional, Zamboni, Stefania, additional, Antonelli, Alessandro, additional, Greco, Francesco, additional, Russo, Giorgio Ivan, additional, Hurle, Rodolfo, additional, Crisan, Nicolae, additional, Manfredi, Matteo, additional, Porpiglia, Francesco, additional, Ribera, Dario, additional, De Placido, Pietro, additional, Facchini, Sergio, additional, Scafuri, Luca, additional, Verde, Antonio, additional, Di Lorenzo, Giuseppe, additional, Cosimato, Vincenzo, additional, Luciano, Angelo, additional, Caputo, Vincenzo Francesco, additional, Crocetto, Felice, additional, and Buonerba, Carlo, additional

Published
2021
Full Text
View/download PDF

28. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis

Author

Ferro, Matteo, primary, de Cobelli, Ottavio, additional, Musi, Gennaro, additional, Lucarelli, Giuseppe, additional, Terracciano, Daniela, additional, Pacella, Daniela, additional, Muto, Tommaso, additional, Porreca, Angelo, additional, Busetto, Gian Maria, additional, Del Giudice, Francesco, additional, Soria, Francesco, additional, Gontero, Paolo, additional, Cantiello, Francesco, additional, Damiano, Rocco, additional, Crocerossa, Fabio, additional, Farhan, Abdal Rahman Abu, additional, Autorino, Riccardo, additional, Vartolomei, Mihai Dorin, additional, Muto, Matteo, additional, Marchioni, Michele, additional, Mari, Andrea, additional, Scafuri, Luca, additional, Minervini, Andrea, additional, Longo, Nicola, additional, Chiancone, Francesco, additional, Perdona, Sisto, additional, De Placido, Pietro, additional, Verde, Antonio, additional, Catellani, Michele, additional, Luzzago, Stefano, additional, Mistretta, Francesco Alessandro, additional, Ditonno, Pasquale, additional, Caputo, Vincenzo Francesco, additional, Battaglia, Michele, additional, Zamboni, Stefania, additional, Antonelli, Alessandro, additional, Greco, Francesco, additional, Russo, Giorgio Ivan, additional, Hurle, Rodolfo, additional, Crisan, Nicolae, additional, Manfredi, Matteo, additional, Porpiglia, Francesco, additional, Di Lorenzo, Giuseppe, additional, Crocetto, Felice, additional, and Buonerba, Carlo, additional

Published
2021
Full Text
View/download PDF

29. The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study.

Author

Di Lorenzo, Giuseppe, Iervolino, Mario, Primiano, Ferdinando, D'Ambrosio, Maurizio, Ingenito, Concetta, Buonerba, Luciana, Busto, Giuseppina, Ferrara, Claudia, Libroia, Annamaria, Ragone, Gianluca, De Falco, Ferdinando, Costabile, Ferdinando, Fimiani, Pietro, Ugliano, Francesco, Ranieri, Chiara, Leo, Emilio, Roviello, Giandomenico, Scafuri, Luca, Guerra, Germano, and Buonerba, Carlo

Subjects
THERAPEUTIC use of antineoplastic agents, REVERSE transcriptase polymerase chain reaction, STATISTICS, COVID-19, MOLECULAR diagnosis, CONFIDENCE intervals, SCIENTIFIC observation, MEDICAL screening, CANCER patients, DESCRIPTIVE statistics, COVID-19 testing, TUMORS, LOGISTIC regression analysis, ODDS ratio
Abstract

Introduction: Cancer aggravates COVID-19 prognosis. Nosocomial transmission of SARS-CoV-2 is particularly frequent in cancer patients, who need to attend hospitals regularly. Since March 2020, all cancer patients having access to the Oncology Unit at the "Andrea Tortora" Hospital (Pagani, Salerno – referred to as "the Hospital") as inpatients or outpatients receiving intravenous therapy have been screened for SARS-CoV-2 using RT-PCR nasal swab. The ongoing COICA (COVID-19 infection in cancer patients) study is an ambispective, multicenter, observational study designed to assess the prognosis of SARS-CoV-2 infection in cancer patients. The aim of the study presented here was to explore potential differences in COVID-19-related outcomes among screening-detected versus nonscreening-detected SARS-CoV-2-infected patients. Methods: The COICA study enrolled cancer patients who had received any anticancer systemic therapy within 3 months since the day they tested positive for SARS-CoV-2 on RT-PCR. The target accrual is 128 patients, and the study was approved by the competent Ethics Committee. Only the subgroup of patients enrolled at the Hospital was considered in this unplanned interim analysis. Logistic regression analysis was used to evaluate the association of screening-based versus nonscreening-based diagnosis. Results: Since March 15, 2020, until August 15, 2021, a total of 931 outpatients and 230 inpatients were repeatedly screened for SARS-CoV-2 using RT-PCR nasal swab at the Hospital. Among these, 71 asymptomatic patients were positive on routine screening and 5 patients were positive for SARS-CoV-2 outside the institutional screening. Seven patients died because of COVID-19. At univariate analysis, nonscreening- versus screening-detected SARS-CoV-2 infection was associated with significantly higher odds of O2 therapy (OR = 16.2; 95% CI = 2.2–117.1; p = 0.006), hospital admission (OR = 31.5; 95% CI = 3.1–317.8; p = 0.003), admission to ICU (OR = 23.0; 95% CI = 2.4–223.8; p = 0.007), and death (OR = 8.8; 95% CI = 1.2–65.5; p = 0.034). Conclusion: Routine screening with RT-PCR may represent a feasible and effective strategy in reducing viral circulation and possibly COVID-19 mortality in patients with active cancer having repeated access to hospital facilities. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department

Author

Allegorico, Enrico, primary, Buonerba, Carlo, additional, Bosso, Giorgio, additional, Pagano, Antonio, additional, Porta, Giovanni, additional, Serra, Claudia, additional, Dolce, Pasquale, additional, Minerva, Valentina, additional, Vicario, Ferdinando Dello, additional, Altruda, Concetta, additional, Arbo, Paola, additional, Russo, Teresa, additional, Sio, Chiara De, additional, Franco, Nicoletta, additional, Ruffa, Gianluca, additional, Mormile, Cinzia, additional, Cannavacciuolo, Francesca, additional, Mercurio, Valentina, additional, Gervasio, Gelsomina, additional, Costanzo, Giuseppe Di, additional, Ragozzino, Alfonso, additional, Scafuri, Luca, additional, Facchini, Gaetano, additional, and Numis, Fabio, additional

Published
2021
Full Text
View/download PDF

32. Assessment of Total, PTEN-, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide.

Author

Di Lorenzo, Giuseppe, Zappavigna, Silvia, Crocetto, Felice, Giuliano, Mario, Ribera, Dario, Morra, Rocco, Scafuri, Luca, Verde, Antonio, Bruzzese, Dario, Iaccarino, Simona, Costabile, Ferdinando, Onofrio, Livia, Viggiani, Martina, Palmieri, Alessandro, De Placido, Pietro, Marretta, Antonella Lucia, Pietroluongo, Erica, Luce, Amalia, Abate, Marianna, and Navaeiseddighi, Zahrasadat

Subjects
PTEN protein, FLOW cytometry, CASTRATION-resistant prostate cancer, CIRCULATING tumor DNA, PROSTATE cancer
Abstract

Assessment of total, PTEN and AR-V7+ circulating tumor cells count by flow cytometry in patients with metastatic castration-resistant prostate cancer receiving enzalutamide. In this study men with metastatic castration resistant prostate cancer, scheduled to start enzalutamide, were assessed for circulating tumor cells count and molecular characterization (total, PTEN and AR-V7+ circulating tumor cells count) by the use of flow cytometry. We found that flow cytometry could be used to enumerate circulating tumor cells, but also to assess molecular biomarkers on their surface. Introduction. Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival (OS) in mCRPC, whereas detection of the androgen-receptor splice variant 7 (AR-V7) in CTC predicts poor response to oral second-generation anti-androgens. Also, loss of PTEN (phosphatase and tensin homolog) in CTC is a biomarker of poor prognosis in mCRPC. Patients and methods. In this translational study, we employed flow cytometry to assess total, PTEN-, and AR-V7+ CTC count per 7.5 mL of whole blood in a prospective cohort of patients with mCRPC receiving enzalutamide. Results. CTCs were assessed in a total of 45 men with mCRPC at baseline and at 12 weeks. Overall, CTC, PTEN- CTC, and AR-V7+ CTC detection rate was high, at baseline, with 84.4%, 71.1%, and 51.1% of samples showing at least 1 cell/7.5-mL blood, respectively, and after 3 months, with 93.3%, 64.4%, and 77.7% of samples showing at least 1 cell/7.5-mL blood, respectively. Median radiographic progression-free survival (rPFS) and OS were 6 (95% confidence interval [CI], 5.6-9) and 14.3 (95% CI, 12.8-20.3) months, respectively. Median (interquartile range) total CTC count at baseline was 5 (3; 8), whereas median (interquartile range) PTEN- CTC count was 2 (0; 4) and median (interquartile range) AR-V7+ CTC count was 1 (0; 3). At baseline, ≥ 5 versus < 5 total CTC count was associated with worse rPFS (hazard ratio [HR], 2.35; 95% CI, 1.14-4.84; P = .021) and OS (HR, 3.08; 95% CI, 1.45-6.54; P = .003), whereas ≥ 2 versus < 2 PTEN- CTC count was associated with worse rPFS (HR, 3.96; 95% CI, 1.8-8.72; P = .001) and OS (HR, 2.36; 95% CI, 1.12-5; P = .025). Finally, ≥ 1 versus < 1 AR-V7+ CTC count was also associated with worse rPFS (HR, 5.05; 95% CI, 2.4-10.64; P < .001) and OS (HR, 2.25; 95% CI, 1.1-4.58; P = .026). Conclusions. Despite multiple limitations, including the small sample size, our preliminary study suggests that assessment of CTC via flow cytometry may provide potentially useful prognostic and predictive information in advanced prostate cancer. Further studies are warranted. Micro-Abstract: In this study, men with metastatic castration-resistant prostate cancer, scheduled to start enzalutamide, were assessed for circulating tumor cell count and molecular characterization (total, PTEN-, and AR-V7+ circulating tumor cell count) by the use of flow cytometry. We found that flow cytometry could be used to enumerate circulating tumor cells, but also to assess molecular biomarkers on their surface. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

Author

Buonerba, Carlo, primary, Iaccarino, Simona, additional, Dolce, Pasquale, additional, Pagliuca, Martina, additional, Izzo, Michela, additional, Scafuri, Luca, additional, Costabile, Ferdinando, additional, Riccio, Vittorio, additional, Ribera, Dario, additional, Mucci, Brigitta, additional, Carrano, Simone, additional, Picozzi, Fernanda, additional, Bosso, Davide, additional, Formisano, Luigi, additional, Bianco, Roberto, additional, De Placido, Sabino, additional, and Di Lorenzo, Giuseppe, additional

Published
2019
Full Text
View/download PDF

34. A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.

Author

Buonerba, Carlo, primary, Grillone, Francesco, additional, Rossetti, Sabrina, additional, Livi, Lorenzo, additional, Scartozzi, Mario, additional, Tagliaferri, Pierosandro, additional, Bruzzese, Dario, additional, Scafuri, Luca, additional, Riccio, Vittorio, additional, Costabile, Ferdinando, additional, Bosso, Davide, additional, Iaccarino, Simona, additional, Facchini, Gaetano, additional, Carrano, Simone, additional, Izzo, Michela, additional, Caraglia, Michele, additional, De Placido, Sabino, additional, and di Lorenzo, Giuseppe, additional

Published
2019
Full Text
View/download PDF

35. Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial

Author

Buonerba, Carlo, primary, De Placido, Pietro, additional, Bruzzese, Dario, additional, Pagliuca, Martina, additional, Ungaro, Paola, additional, Bosso, Davide, additional, Ribera, Dario, additional, Iaccarino, Simona, additional, Scafuri, Luca, additional, Liotti, Antonietta, additional, Romeo, Valeria, additional, Izzo, Michela, additional, Perri, Francesco, additional, Casale, Beniamino, additional, Grimaldi, Giuseppe, additional, Vitrone, Francesca, additional, Brunetti, Arturo, additional, Terracciano, Daniela, additional, Marinelli, Alfredo, additional, De Placido, Sabino, additional, and Di Lorenzo, Giuseppe, additional

Published
2018
Full Text
View/download PDF

36. The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

Author

Buonerba, Carlo, primary, Sonpavde, Guru, additional, Vitrone, Francesca, additional, Bosso, Davide, additional, Puglia, Livio, additional, Izzo, Michela, additional, Iaccarino, Simona, additional, Scafuri, Luca, additional, Muratore, Margherita, additional, Foschini, Francesca, additional, Mucci, Brigitta, additional, Tortora, Vincenzo, additional, Pagliuca, Martina, additional, Ribera, Dario, additional, Riccio, Vittorio, additional, Morra, Rocco, additional, Mosca, Mirta, additional, Cesarano, Nicola, additional, Di Costanzo, Ileana, additional, De Placido, Sabino, additional, and Di Lorenzo, Giuseppe, additional

Published
2017
Full Text
View/download PDF

37. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Author

Buonerba, Carlo, Dolce, Pasquale, Iaccarino, Simona, Scafuri, Luca, Verde, Antonio, Costabile, Ferdinando, Pagliuca, Martina, Morra, Rocco, Riccio, Vittorio, Ribera, Dario, De Placido, Pietro, Romeo, Valeria, Crocetto, Felice, Longo, Nicola, Imbimbo, Ciro, De Placido, Sabino, and Di Lorenzo, Giuseppe

Subjects
ANTINEOPLASTIC agents, CONFIDENCE intervals, IMMUNOTHERAPY, MEDICAL databases, INFORMATION storage & retrieval systems, MEDICAL information storage & retrieval systems, MEDLINE, META-analysis, ONLINE information services, RENAL cell carcinoma, SARCOMA, SYSTEMATIC reviews, TREATMENT effectiveness, DESCRIPTIVE statistics, EVALUATION
Abstract

Immunotherapy based on anti PD-1/PD-L1 inhibitors has proven to be more effective than sunitinib in the first-line setting of advanced renal cell carcinoma (RCC). RCC patients with sarcomatoid histology (sRCC) have a poor prognosis and limited therapeutic options. We performed a systematic review and a meta-analysis of randomized-controlled trials (RCTs) of first-line anti PD-1/PDL-1 agents vs. sunitinib, presenting efficacy data in the sub-group of sRCC patients. The systematic research was conducted on Google Scholar, Cochrane Library, PubMed and Embase and updated until 31th January, 2020. Abstracts from ESMO and ASCO (2010–2019) were also reviewed. Full texts and abstracts reporting about RCTs testing first-line anti-PD-1/ PD-L1 agents vs. sunitinib in RCC were included if sRCC sub-group analyses of either PFS (progression-free survival), OS (overall survival) or radiological response rate were available. Pooled data from 3814 RCC patients in the ITT (intention-to-treat) population and from 512 sRCC patients were included in the quantitative synthesis. In the sRCC sub-group vs. the ITT population, pooled estimates of the PFS-HRs were 0.57 (95%: 0.45–0.74) vs. 0.79 (95% CI: 0.70–0.89), respectively, with a statistically meaningful interaction favoring the sRCC sub-group (pooled ratio of the PFS-HRs = 0.64; 95% CI: 0.50–0.82; p < 0.001). Pooled estimates of the difference in CR-R (complete response-rate) achieved with anti-PD-1/PDL-1 agents vs. sunitinib were + 0.10 (95% CI: 0.04–0.16) vs. + 0.04 (95% CI: 0.00–0.07) in the sRCC vs. the non-sRCC sub groups, with a statistically meaningful difference of + 0.06 (95% CI: 0.02–0.10; p = 0.007) favoring the sRCC sub-group. Sarcomatoid histology may be associated with improved efficacy of anti PD-1/PDL-1 agents vs. sunitinib in terms of PFS and CR-R. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

38. Assessment of Total, PTEN–, and AR-V7+Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Author

Di Lorenzo, Giuseppe, Zappavigna, Silvia, Crocetto, Felice, Giuliano, Mario, Ribera, Dario, Morra, Rocco, Scafuri, Luca, Verde, Antonio, Bruzzese, Dario, Iaccarino, Simona, Costabile, Ferdinando, Onofrio, Livia, Viggiani, Martina, Palmieri, Alessandro, De Placido, Pietro, Marretta, Antonella Lucia, Pietroluongo, Erica, Luce, Amalia, Abate, Marianna, Navaeiseddighi, Zahrasadat, Caputo, Vincenzo Francesco, Celentano, Giuseppe, Longo, Nicola, Ferro, Matteo, Morelli, Franco, Facchini, Gaetano, Caraglia, Michele, De Placido, Sabino, and Buonerba, Carlo

Abstract

Introduction. Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival (OS) in mCRPC, whereas detection of the androgen-receptor splice variant 7 (AR-V7) in CTC predicts poor response to oral second-generation anti-androgens. Also, loss of PTEN (phosphatase and tensin homolog) in CTC is a biomarker of poor prognosis in mCRPC. Patients and methods. In this translational study, we employed flow cytometry to assess total, PTEN–, and AR-V7+CTC count per 7.5 mL of whole blood in a prospective cohort of patients with mCRPC receiving enzalutamide. Results. CTCs were assessed in a total of 45 men with mCRPC at baseline and at 12 weeks. Overall, CTC, PTEN–CTC, and AR-V7+CTC detection rate was high, at baseline, with 84.4%, 71.1%, and 51.1% of samples showing at least 1 cell/7.5-mL blood, respectively, and after 3 months, with 93.3%, 64.4%, and 77.7% of samples showing at least 1 cell/7.5-mL blood, respectively. Median radiographic progression-free survival (rPFS) and OS were 6 (95% confidence interval [CI], 5.6-9) and 14.3 (95% CI, 12.8-20.3) months, respectively. Median (interquartile range) total CTC count at baseline was 5 (3; 8), whereas median (interquartile range) PTEN–CTC count was 2 (0; 4) and median (interquartile range) AR-V7+CTC count was 1 (0; 3). At baseline, ≥ 5 versus < 5 total CTC count was associated with worse rPFS (hazard ratio [HR], 2.35; 95% CI, 1.14-4.84; P= .021) and OS (HR, 3.08; 95% CI, 1.45-6.54; P= .003), whereas ≥ 2 versus < 2 PTEN–CTC count was associated with worse rPFS (HR, 3.96; 95% CI, 1.8-8.72; P= .001) and OS (HR, 2.36; 95% CI, 1.12-5; P= .025). Finally, ≥ 1 versus < 1 AR-V7+CTC count was also associated with worse rPFS (HR, 5.05; 95% CI, 2.4-10.64; P< .001) and OS (HR, 2.25; 95% CI, 1.1-4.58; P= .026). Conclusions. Despite multiple limitations, including the small sample size, our preliminary study suggests that assessment of CTC via flow cytometry may provide potentially useful prognostic and predictive information in advanced prostate cancer. Further studies are warranted.

Published
2021
Full Text
View/download PDF

39. A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy

Author

Nicola Longo, Daniela Terracciano, Francesco Del Giudice, Giuseppe Lucarelli, Angelo Porreca, Pasquale Ditonno, Angelo Luciano, Carlo Buonerba, Alessandro Antonelli, Vincenzo Caputo, Rocco Damiano, Pasquale Dolce, Michele Marchioni, Fabio Crocerossa, Paolo Gontero, Stefania Zamboni, Matteo Manfredi, Antonio Verde, Michele Battaglia, Dario Ribera, Francesco Porpiglia, Gennaro Musi, Francesco Cantiello, Andrea Minervini, Felice Crocetto, Ottavio De Cobelli, Giuseppe Celentano, Vincenzo Cosimato, Mihai Dorin Vartolomei, Nicolae Crisan, Andrea Mari, Giorgio Ivan Russo, Abdal Rahman Abu Farhan, Francesco Greco, Francesco Soria, Francesco Chiancone, Luca Scafuri, Paola Del Prete, Rodolfo Hurle, Pietro De Placido, Giuseppe Di Lorenzo, Sergio Facchini, Matteo Ferro, Riccardo Autorino, Sisto Perdonà, Gian Maria Busetto, Ferro, Matteo, Lucarelli, Giuseppe, de Cobelli, Ottavio, Dolce, Pasquale, Terracciano, Daniela, Musi, Gennaro, Porreca, Angelo, Busetto, Gian Maria, Del Giudice, Francesco, Soria, Francesco, Gontero, Paolo, Cantiello, Francesco, Damiano, Rocco, Crocerossa, Fabio, Abu Farhan, Abdal Rahman, Autorino, Riccardo, Vartolomei, Mihai Dorin, Marchioni, Michele, Mari, Andrea, Minervini, Andrea, Longo, Nicola, Celentano, Giuseppe, Chiancone, Francesco, Perdonà, Sisto, Del Prete, Paola, Ditonno, Pasquale, Battaglia, Michele, Zamboni, Stefania, Antonelli, Alessandro, Greco, Francesco, Russo, Giorgio Ivan, Hurle, Rodolfo, Crisan, Nicolae, Manfredi, Matteo, Porpiglia, Francesco, Ribera, Dario, De Placido, Pietro, Facchini, Sergio, Scafuri, Luca, Verde, Antonio, Di Lorenzo, Giuseppe, Cosimato, Vincenzo, Luciano, Angelo, Caputo, Vincenzo Francesco, Crocetto, Felice, and Buonerba, Carlo

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, 030232 urology & nephrology, Cystectomy, Neoadjuvant chemotherapy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Survival rate, Aged, Retrospective Studies, Cisplatin, Chemotherapy, Bladder cancer, business.industry, Cholesterol, Combination chemotherapy, General Medicine, Middle Aged, medicine.disease, Radical cystectomy, Urinary Bladder Neoplasms, chemistry, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Lymphadenectomy, business, medicine.drug
Abstract

The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationale for exploring novel treatments. Patients included had histologically confirmed urothelial bladder cancer and were treated with at least 3 cycles of cisplatin-based neoadjuvant chemotherapy before radical cystectomy with lymphadenectomy. A total of 245 patients at low, intermediate and high risk, presenting with 0-1, 2 or 3-4 risk factors, including positive lymph nodes, Hb 12.8, NLR ≥2.7 and cholesterol levels ≥199, were included. Five-year cancer-specific survival rate was 0.67, 0.78 and 0.94 at high, intermediate and low risk, respectively. Total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and may be incorporated in a clinically meaningful risk-group classification model.Lay abstract This present study assessed a large group of patients with urothelial bladder cancer treated with chemotherapy followed by radical cystectomy, to capture the predictive power of commonly collected clinical, pathological and biochemical factors. The design of the study highlighted that higher cholesterol levels at the time of cystectomy were associated with shorter cancer-specific survival. This finding suggests that high blood-cholesterol levels truly have a negative influence on surviving cancer. In conclusion, total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and could be incorporated into a clinically meaningful and valuable risk-group classification model.

Published
2021
Full Text
View/download PDF

40. Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?

Author

Roberto Sanseverino, Giuseppe Di Lorenzo, Francesco Ugliano, Carlo Buonerba, Germano Guerra, Felice Crocetto, Antonella Sciarra, Matteo Ferro, Luca Scafuri, Scafuri, L., Sciarra, A., Crocetto, F., Ferro, M., Buonerba, C., Ugliano, F., Guerra, G., Sanseverino, R., Lorenzo, G. D., Scafuri, Luca, Sciarra, Antonella, Crocetto, Felice, Ferro, Matteo, Buonerba, Carlo, Ugliano, Francesco, Guerra, Germano, Sanseverino, Roberto, and Lorenzo, Giuseppe Di

Subjects
medicine.medical_specialty, Bladder cancer, business.industry, medicine.medical_treatment, Muscle invasive, Urology, adjuvant therapy, Perioperative, bladder cancer, neoadjuvant therapy, medicine.disease, Systemic therapy, Editorial, medicine, Adjuvant therapy, business, Neoadjuvant therapy, Biotechnology, Urothelial carcinoma
Published
2021

41. Contralateral prophylactic mastectomy in male breast cancer: where do we stand?

Author

Antonella Sciarra, Luca Scafuri, Giuseppe Di Lorenzo, Carlo Buonerba, Sciarra, Antonella, Buonerba, Carlo, Lorenzo, Giuseppe Di, and Scafuri, Luca

Subjects
medicine.medical_specialty, business.industry, male breast cancer, medicine.disease, law.invention, Surgery, Contralateral Prophylactic Mastectomy, Editorial, Randomized controlled trial, law, contralateral prophylactic mastectomy, Male breast cancer, randomized controlled trials, Medicine, business, Biotechnology
Published
2021

42. Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review

Author

Biagio Barone, Armando Calogero, Luca Scafuri, Matteo Ferro, Giuseppe Lucarelli, Erika Di Zazzo, Enrico Sicignano, Alfonso Falcone, Lorenzo Romano, Luigi De Luca, Francesco Oliva, Benito Fabio Mirto, Federico Capone, Ciro Imbimbo, Felice Crocetto, Barone, Biagio, Calogero, Armando, Scafuri, Luca, Ferro, Matteo, Lucarelli, Giuseppe, Di Zazzo, Erika, Sicignano, Enrico, Falcone, Alfonso, Romano, Lorenzo, De Luca, Luigi, Oliva, Francesco, Mirto, Benito Fabio, Capone, Federico, Imbimbo, Ciro, and Crocetto, Felice

Subjects
Cancer Research, adjuvant, Oncology, muscle-invasive bladder cancer, neoadjuvant, immune checkpoint inhibitor
Abstract

Bladder cancer is the ninth most common cancer worldwide. Over 75% of non-muscle invasive cancer patients require conservative local treatment, while the remaining 25% of patients undergo radical cystectomy or radiotherapy. Immune checkpoint inhibitors represent a novel class of immunotherapy drugs that restore natural antitumoral immune activity via the blockage of inhibitory receptors and ligands expressed on antigen-presenting cells, T lymphocytes and tumour cells. The use of immune checkpoint inhibitors in bladder cancer has been expanded from the neoadjuvant setting, i.e., after radical cystectomy, to the adjuvant setting, i.e., before the operative time or chemotherapy, in order to improve the overall survival and to reduce the morbidity and mortality of both the disease and its treatment. However, some patients do not respond to checkpoint inhibitors. As result, the capability for identifying patients that are eligible for this immunotherapy represent one of the efforts of ongoing studies. The aim of this systematic review is to summarize the most recent evidence regarding the use of immune checkpoint inhibitors, in a neoadjuvant and adjuvant setting, in the treatment of muscle-invasive bladder cancer.

Published
2022
Full Text
View/download PDF

43. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis

Author

Matteo Ferro, Ottavio de Cobelli, Gennaro Musi, Giuseppe Lucarelli, Daniela Terracciano, Daniela Pacella, Tommaso Muto, Angelo Porreca, Gian Maria Busetto, Francesco Del Giudice, Francesco Soria, Paolo Gontero, Francesco Cantiello, Rocco Damiano, Fabio Crocerossa, Abdal Rahman Abu Farhan, Riccardo Autorino, Mihai Dorin Vartolomei, Matteo Muto, Michele Marchioni, Andrea Mari, Luca Scafuri, Andrea Minervini, Nicola Longo, Francesco Chiancone, Sisto Perdona, Pietro De Placido, Antonio Verde, Michele Catellani, Stefano Luzzago, Francesco Alessandro Mistretta, Pasquale Ditonno, Vincenzo Francesco Caputo, Michele Battaglia, Stefania Zamboni, Alessandro Antonelli, Francesco Greco, Giorgio Ivan Russo, Rodolfo Hurle, Nicolae Crisan, Matteo Manfredi, Francesco Porpiglia, Giuseppe Di Lorenzo, Felice Crocetto, Carlo Buonerba, Ferro, Matteo, de Cobelli, Ottavio, Musi, Gennaro, Lucarelli, Giuseppe, Terracciano, Daniela, Pacella, Daniela, Muto, Tommaso, Porreca, Angelo, Busetto, Gian Maria, Del Giudice, Francesco, Soria, Francesco, Gontero, Paolo, Cantiello, Francesco, Damiano, Rocco, Crocerossa, Fabio, Farhan, Abdal Rahman Abu, Autorino, Riccardo, Vartolomei, Mihai Dorin, Muto, Matteo, Marchioni, Michele, Mari, Andrea, Scafuri, Luca, Minervini, Andrea, Longo, Nicola, Chiancone, Francesco, Perdona, Sisto, De Placido, Pietro, Verde, Antonio, Catellani, Michele, Luzzago, Stefano, Mistretta, Francesco Alessandro, Ditonno, Pasquale, Caputo, Vincenzo Francesco, Battaglia, Michele, Zamboni, Stefania, Antonelli, Alessandro, Greco, Francesco, Russo, Giorgio Ivan, Hurle, Rodolfo, Crisan, Nicolae, Manfredi, Matteo, Porpiglia, Francesco, Di Lorenzo, Giuseppe, Crocetto, Felice, and Buonerba, Carlo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, bladder cancer, cisplatin-based chemotherapy, neoadjuvant chemotherapy, observational study, radical cystectomy, medicine.medical_treatment, 030232 urology & nephrology, Cystectomy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, RC254-282, Neoadjuvant therapy, Original Research, Univariate analysis, Bladder cancer, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, Retrospective cohort study, medicine.disease, 030220 oncology & carcinogenesis, Cohort, Lymphadenectomy, business
Abstract

BackgroundThree or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also commonly administered in clinical practice. In this multicenter retrospective study, we assessed a large and homogenous cohort of patients with urothelial bladder cancer (UBC) treated with three or four cycles of neoadjuvant cisplatin-gemcitabine followed by radical cystectomy, in order to explore whether three vs. four cycles were associated with different outcomes.MethodsPatients with histologically confirmed muscle-invasive UBC included in this retrospective study had to be treated with either 3 (cohort A) or 4 (cohort B) cycles of cisplatin-gemcitabine as neoadjuvant therapy before undergoing radical cystectomy with lymphadenectomy. Outcomes including pathologic downstaging to non-muscle invasive disease, pathologic complete response (defined as absence of disease -ypT0), overall- and cancer-specific- survival as well as time to recurrence were compared between cohorts A vs. B.ResultsA total of 219 patients treated at 14 different high-volume Institutions were included in this retrospective study. Patients who received 3 (cohort A) vs. 4 (cohort B) cycles of neoadjuvant cisplatin-gemcitabine were 160 (73,1%) vs. 59 (26,9%).At univariate analysis, the number of neoadjuvant cycles was not associated with either pathologic complete response, pathologic downstaging, time to recurrence, cancer specific, and overall survival. Of note, patients in cohort B vs. A showed a worse non-cancer specific overall survival at univariate analysis (HR= 2.53; 95 CI= 1.05 - 6.10; p=0.046), although this finding was not confirmed at multivariate analysis.ConclusionsOur findings suggest that 3 cycles of cisplatin-gemcitabine may be equally effective, with less long-term toxicity, compared to 4 cycles in the neoadjuvant setting.

Published
2021

44. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Author

Luca Scafuri, Giuseppe Di Lorenzo, Antonio Verde, Vittorio Riccio, Sabino De Placido, Ciro Imbimbo, Nicola Longo, Valeria Romeo, Felice Crocetto, Pasquale Dolce, Pietro De Placido, Martina Pagliuca, Carlo Buonerba, Rocco Morra, Dario Ribera, Ferdinando Costabile, Simona Iaccarino, Buonerba, Carlo, Dolce, Pasquale, Iaccarino, Simona, Scafuri, Luca, Verde, Antonio, Costabile, Ferdinando, Pagliuca, Martina, Morra, Rocco, Riccio, Vittorio, Ribera, Dario, DE PLACIDO, Pietro, Romeo, Valeria, Crocetto, Felice, Longo, Nicola, Imbimbo, Ciro, DE PLACIDO, Sabino, and Di Lorenzo, Giuseppe

Subjects
Oncology, Cancer Research, medicine.medical_specialty, renal cell carcinoma, Population, Review, Cochrane Library, lcsh:RC254-282, immune checkpoint inhibitors, 03 medical and health sciences, 0302 clinical medicine, pd-l1, Renal cell carcinoma, PD-L1, Internal medicine, medicine, In patient, 030212 general & internal medicine, education, Response rate (survey), education.field_of_study, biology, Sunitinib, business.industry, sarcomatoid, pd-1, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030220 oncology & carcinogenesis, Meta-analysis, biology.protein, business, medicine.drug
Abstract

Immunotherapy based on anti PD-1/PD-L1 inhibitors has proven to be more effective than sunitinib in the first-line setting of advanced renal cell carcinoma (RCC). RCC patients with sarcomatoid histology (sRCC) have a poor prognosis and limited therapeutic options. We performed a systematic review and a meta-analysis of randomized-controlled trials (RCTs) of first-line anti PD-1/PDL-1 agents vs. sunitinib, presenting efficacy data in the sub-group of sRCC patients. The systematic research was conducted on Google Scholar, Cochrane Library, PubMed and Embase and updated until 31th January, 2020. Abstracts from ESMO and ASCO (2010−2019) were also reviewed. Full texts and abstracts reporting about RCTs testing first-line anti-PD-1/ PD-L1 agents vs. sunitinib in RCC were included if sRCC sub-group analyses of either PFS (progression-free survival), OS (overall survival) or radiological response rate were available. Pooled data from 3814 RCC patients in the ITT (intention-to-treat) population and from 512 sRCC patients were included in the quantitative synthesis. In the sRCC sub-group vs. the ITT population, pooled estimates of the PFS-HRs were 0.57 (95%: 0.45−0.74) vs. 0.79 (95% CI: 0.70−0.89), respectively, with a statistically meaningful interaction favoring the sRCC sub-group (pooled ratio of the PFS-HRs = 0.64; 95% CI: 0.50−0.82; p < 0.001). Pooled estimates of the difference in CR-R (complete response-rate) achieved with anti-PD-1/PDL-1 agents vs. sunitinib were + 0.10 (95% CI: 0.04−0.16) vs. + 0.04 (95% CI: 0.00−0.07) in the sRCC vs. the non-sRCC sub groups, with a statistically meaningful difference of + 0.06 (95% CI: 0.02−0.10; p = 0.007) favoring the sRCC sub-group. Sarcomatoid histology may be associated with improved efficacy of anti PD-1/PDL-1 agents vs. sunitinib in terms of PFS and CR-R.

Published
2020

45. Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial

Author

Carlo Buonerba, Pietro De Placido, Dario Bruzzese, Martina Pagliuca, Paola Ungaro, Davide Bosso, Dario Ribera, Simona Iaccarino, Luca Scafuri, Antonietta Liotti, Valeria Romeo, Michela Izzo, Francesco Perri, Beniamino Casale, Giuseppe Grimaldi, Francesca Vitrone, Arturo Brunetti, Daniela Terracciano, Alfredo Marinelli, Sabino De Placido, Giuseppe Di Lorenzo, Buonerba, Carlo, DE PLACIDO, Pietro, Bruzzese, Dario, Pagliuca, Martina, Ungaro, Paola, Bosso, Davide, Ribera, Dario, Iaccarino, Simona, Scafuri, Luca, Liotti, Antonietta, Romeo, Valeria, Izzo, Michela, Perri, Francesco, Casale, Beniamino, Grimaldi, Giuseppe, Vitrone, Francesca, Brunetti, Arturo, Terracciano, Daniela, Marinelli, Alfredo, De Placido, Sabino, and Di Lorenzo, Giuseppe

Subjects
0301 basic medicine, Drug, medicine.medical_specialty, Isoquercertin, media_common.quotation_subject, sunitinib, isoquercetin, Gastroenterology, phase I trial, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pharmacokinetics, Renal cell carcinoma, Internal medicine, medicine, Pharmacology (medical), Adverse effect, media_common, Pharmacology, AMP-activated protein kinase, Sunitinib, business.industry, AMP-activated protein kinases, lcsh:RM1-950, kidney cancer, medicine.disease, Clinical Trial, phase I trials, 030104 developmental biology, lcsh:Therapeutics. Pharmacology, chemistry, 030220 oncology & carcinogenesis, Isoquercetin, Cohort, business, Kidney cancer, medicine.drug
Abstract

Sunitinib is the most commonly prescribed drug for advanced renal cell carcinoma in the first-line setting and has been associated with multiple adverse events related to its on–and off–target effects, including hand and foot syndrome and fatigue. It was hypothesized that sunitinib-induced fatigue may be related to off target inhibition of the AMPK enzyme, which results in impairment of energy-producing processes at a systemic level. Quercetin is a naturally occurring flavonol with established AMPK-stimulating activity. While clinical use of quercetin is limited by its poor bio-availability, quercetin-3-O-β-d-glucopyranoside, that is isoquercetin, has an improved pharmacokinetic profile. On the grounds of the in vitro stimulatory activity with respect to AMPk, we hypothesized that oral isoquercetin could improve fatigue in kidney cancer patients receiving sunitinib. Given the lack of data on the safety of isoquercetin given concomitantly with sunitinib, we conducted a phase I trial to assess the safety of GMP manufactured isoquercetin given at two dose levels (450 and 900 mg a day). In the 12-patient study cohort included in this study, isoquercetin was administered concomitantly with 50 mg sunitinib for a median 81 days (IQR, 75.5, 86.5). None of the 12 patients required isoquercetin suspension or isoquercetin dose reduction because of adverse events. No abnormalities in ECG, heart or lower limbs doppler ultrasound were detected. A statistically significant improvement was reported for the FACIT fatigue score (6.8 points; 95% CI: 2.8–10.8; p = 0.002) and for the FACIT Adverse Events score (18.9 points; 95% CI: 9.1–28.8; p < 0.001) after isoquercetin consumption vs. baseline. In this phase I trial, isoquercetin was remarkably safe, with a preliminary signal of activity in terms of improvement of sunitinib adverse events.

Published
2018
Full Text
View/download PDF

46. Supplements in Oncology: Uses, Hurdles, Guidance, and Future Perspectives.

Author

Scafuri L, Buonerba C, Amato AR, Verde A, Montanaro V, Marotta V, Riccio V, Fortino F, and Di Lorenzo G

Abstract

This editorial explores the intricate landscape of supplement use in oncology, highlighting the growing interest and challenges surrounding their integration into cancer care. It discusses the disparity in regulatory oversight between supplements and pharmaceutical drugs, the blurred lines in their classification, and the ethical complexities in patient-doctor communication. The importance of transparency, shared decision-making, and realistic expectations is emphasized. While acknowledging the value of traditional research models, the editorial advocates for innovative approaches like retrospective studies, biomarker analysis, and personalized medicine to advance our understanding of supplement efficacy and safety. By integrating these diverse perspectives, we can unlock the full potential of supplements in oncology, ensuring that they are used effectively and responsibly to enhance patient outcomes., (S. Karger AG, Basel.)

Published
2025
Full Text
View/download PDF

48. The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department.

Author

Allegorico E, Buonerba C, Bosso G, Pagano A, Porta G, Serra C, Dolce P, Minerva V, Vicario FD, Altruda C, Arbo P, Russo T, Sio C, Franco N, Ruffa G, Mormile C, Cannavacciuolo F, Mercurio V, Gervasio G, Costanzo GD, Ragozzino A, Scafuri L, Facchini G, and Numis F

Abstract

Aim: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus-specific reverse transcriptase-polymerase chain reaction (RT-PCR) represents the diagnostic gold standard. We explored the value of chest ultrasonography to predict positivity to SARS-CoV-2 on RT-PCR in suspected COVID-19 cases., Patients & Methods: Consecutive patients with suspect COVID-19 were included if they had fever and/or history of cough and/or dyspnea. Lung ultrasound score (LUSS) was computed according to published methods., Results: A total of 76 patients were included. A 3-variable model based on aspartate transaminase (AST) > upper limit of normal, LUSS >12 and body temperature >37.5°C yielded an overall accuracy of 91%., Conclusion: A simple LUSS-based model may represent a powerful tool for initial assessment in suspected cases of COVID-19., Competing Interests: Financial & competing interests disclosure C Buonerba is a member of the Future Science OA Editorial Board. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript., (© 2020 Enrico Allegorico.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results